Irritable bowel syndrome in quiescent inflammatory bowel disease: A review

Minerva Gastroenterologica e Dietologica

Volumn 61, Issue 4, 2015, Pages 201-213

  Burgell, R E ^a   Asthana, A K ^a   Gibson, P R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Colitis, ulcerative; Crohn disease; Irritatile bowel syndrome

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

DIET THERAPY; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPNOSIS; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE INNERVATION; IRRITABLE COLON; NERVOUS SYSTEM INFLAMMATION; PATHOGENESIS; PELVIC FLOOR MUSCLE TRAINING; PHYSIOTHERAPY; QUALITY OF LIFE; REVIEW; SENSORY DYSFUNCTION; VISCERAL PAIN; BRAIN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFLAMMATORY BOWEL DISEASES; INNERVATION; INTESTINE; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; MICROFLORA; PATHOPHYSIOLOGY; PHYSIOLOGY;

BRAIN; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATORY BOWEL DISEASES; INTESTINES; IRRITABLE BOWEL SYNDROME; MICROBIOTA; PITUITARY-ADRENAL SYSTEM; QUALITY OF LIFE;

EID: 84962496959     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol 2015;50:942-51.
2. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965-90.
3. Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013;145:996-1006.
4. Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010;105:1480-7.
5. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 Suppl 1:116-35.
6. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014;6:71-80.
7. El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: Natural history of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19:861-70.
8. Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006;12:38-46.
9. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review' and metaanalysis. Am J Gastroenterol 2012;107:1474-82.
10. Fukuba N, Ishihara S, Tada Y, Oshima N, Moriyama I, Yuki T, et al. Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study. Scand J Gastroenterol 2014;49:674-80.
11. Jonefjall B, Simren M, Ohman L, Lasson A, Svedlund J, Strid H. The severity of inflammation at onset of ulcerative colitis is not associated with IBS-like symptoms during clincal remission. 2015 Sep;9:776-83.
12. Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002;97:389-96.
13. Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrometype symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010;105:1788, 1789-94; quiz 1795.
14. Bouin M, Meunier P, Riberdy-Poitras M, Poitras P. Pain hypersensitivity in patients with functional gastrointestinal disorders: a gastrointestinal-specific defect or a general systemic condition? Dig Dis Sci 2001;46:2542-8.
15. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994;107:271-93.
16. Zhou Q, Fillingim RB, Riley JL, 3rd, Malarkey WB, Verne GN. Central and peripheral hypersensitivity in the irritable bowel syndrome. Pain 2010;148:454-61.
17. Dupont AW. Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep 2007;9:378-84.
18. Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005;129:98-104.
19. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003;124:1662-71.
20. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery Gut 2010;59:605-11.
21. Schwille-Kiuntke J, Mazurak N, Enck P. Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers' diarrhoea. Aliment Pharmacol Ther 2015;41:1029-37.
22. Vivinus-Nebot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 2014;63:744-52.
23. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005;34:235-45, vi-vii.
24. Porter CK, Tribble DR, Aliaga PA, Halvorson HA, Riddle MS. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 2008;135:781-6.
25. Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 2006;130:1588-94.
26. Hobday DI, Aziz Q, Thacker N, Hollander I, Jackson A, Thompson DG. A study of the cortical processing of ano-rectal sensation using functional MRI. Brain 2001;124:361-8.
27. Ladabaum U, Minoshima S, Hasler WL, Cross D, Chey TO, Owyang C. Gastric distention correlates with activation of multiple cortical and subcortical regions. Gastroenterology 2001;120:369-76.
28. Mertz H, Morgan V, Tanner G, Pickens D, Price R, Shyr Y, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000;118:842-8.
29. Coss-Adame E, Rao SS. Brain and gut interactions in irritable bowel syndrome: new paradigms and new understandings. Curr Gastroenterol Rep 2014;16:379.
30. Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis 2009;15:778-88.
31. Hansen MB. The enteric nervous system I: organisation and classification. Pharmacol Toxicol 2003;92:105-13.
32. Berthoud HR, Blackshaw LA, Brookes SJ, Grundy D. Neuroanatomy of extrinsic afferents supplying the gastrointestinal tract. Neurogastroenterol Motil 2004;16 Suppl 1:28-33.
33. Straub RH, Herfarth H, Falk W, Andus T, Scholmerich J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J Neuroimmunol 2002;126:116-25.
34. Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut 2000;47:861-9.
35. Thijssen AY, Jonkers DM, Leue C, van der Veek PP, Vidakovic-Vukic M, van Rood YR, et al. Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome. J Clin Gastroenterol 2010;44:e236-41.
36. Fukudo S, Kanazawa M, Kano M, Sagami Y, Endo Y, Utsumi A, et al. Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. J Gastroenterol 2002;37 Suppl 14:145-50.
37. Farmer AD, Aziz Q. Visceral pain hypersensitivity in functional gastrointestinal disorders. Br Med Bull 2009;91:123-36.
38. Cenac N. Protease-activated receptors as therapeutic targets in visceral pain. Curr Neuropharmacol 2013;11:598-605.
39. Vergnolle N. Review article: proteinase-activated receptors - novel signals for gastrointestinal pathophysiology. Aliment Pharmacol Ther 2000;14:257-66.
40. Vergnolle N, Ferazzini M, D'Andrea MR, Buddenkotte J, Steinhoff M. Proteinase-activated receptors: novel signals for peripheral nerves. Trends Neurosci 2003;26:496-500.
41. Akbar A, Walters JR, Ghosh S. Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents. Aliment Pharmacol Ther 2009;30:423-35.
42. Lakhan SE, Kirchgessner A. Neuroinflammation in inflammatory bowel disease. J Neuroinflammation 2010;7:37.
43. De Giorgio R, Guerrini S, Barbara G, Stanghellini V, De Ponti F, Corinaldesi R, et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004;126:1872-83.
44. Geboes K, Collins S. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol Motil 1998;10:189-202.
45. Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993;88:908-13.
46. Lapointe TK, Basso L, Iftinca MC, Flynn R, Chapman K, Dietrich G, et al. TRPV1 sensitization me-diates postinflammatory visceral pain following acute colitis. Am J Physiol Gastrointest Liver Physiol 2015;309:G87-99.
47. Matsumoto K, Lo MW, Hosoya T, Tashima K, Takayama H, Murayama T, et al. Experimental colitis alters expression of 5-HT receptors and transient receptor potential vanilloid 1 leading to visceral hypersensitivity in mice. Lab Invest 2012;92:769-82.
48. Aguas M, Garrigues V, Bastida G, Nos P, Ortiz V, Fernandez A, et al. Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD). J Crohns Colitis 2011;5:227-33.
49. Mondot S, de Wouters T, Dore J, Lepage P. The human gut microbiome and its dysfunctions. Dig Dis 2013;31:278-85.
50. Jeffery IB, O'Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012;61:997-1006.
51. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731-6.
52. Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, et al. Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease. PLoS One 2012;7:e41594.
53. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012;13:R79.
54. Major G, Spiller R. Irritable bowel syndrome, inflammatory bowel disease and the microbiome. Curr Opin Endocrinol Diabetes Obes 2014;21:15-21.
55. Zenewicz LA, Yin X, Wang G, Elinav E, Hao L, Zhao L, et al. IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic. J Immunol 2013;190:5306-12.
56. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and metaanalysis. Am J Gastroenterol 2014;109:1350-65; quiz 1366.
57. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109 Suppl 1:S2-26; quiz S27.
58. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014;146:67-75 e5.
59. Eadala P, Matthews SB, Waud JP, Green JT, Campbell AK. Association of lactose sensitivity with inflammatory bowel disease-demonstrated by analysis of genetic polymorphism, breath gases and symptoms. Aliment Pharmacol Ther 2011;34:735-46.
60. Gearry RB, Irving PM, Barrett JS, Nathan DM, Shepherd SJ, Gibson PR. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohns Colitis 2009;3:8-14.
61. Davies PS, Rhodes J. Maintenance of remission in ulcerative colitis with sulphasalazine or a high-fiber diet: a clinical trial. Br Med J 1978;1:1524-5.
62. Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 1991;26:747-50.
63. Wedlake L, Slack N, Andreyev HJ, Whelan K. Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic review of randomized controlled trials. Inflamm Bowel Dis 2014;20:576-86.
64. Herfarth HH, Martin CF, Sandler RS, Kappelman MD, Long MD. Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2014;20:1194-7.
65. Aziz I, Branchi F, Pearson K, Priest J, Sanders DS. A study evaluating the bidirectional relationship between inflammatory bowel disease and self-reported non-celiac gluten sensitivity. Inflamm Bowel Dis 2015;21:847-53.
66. Gibson PR, Muir JG, Newnham ED. Other Dietary Confounders: FODMAPS et al. Dig Dis 2015;33:269-76.
67. De Giorgio R, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction? Gut [Epub ahead of print on June 15, 2015].
68. Staudacher H, Gibson PR. How healthy is a glutenfree diet? Br J Nutr [Epub ahead of print on September 15, 2015].
69. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012;72:803-23.
70. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
71. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and metaanalysis. Am J Gastroenterol 2014;109:1547-61; quiz 1546, 1562.
72. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7:1279-86.
73. Sanchez-Montes C, Ortiz V, Bastida G, Rodriguez E, Yago M, Beltran B, et al. Small intestinal bacterial overgrowth in inactive Crohn's disease: influence of thiopurine and biological treatment. World J Gastroenterol 2014;20:13999-4003.
74. Rana SV, Sharma S, Malik A, Kaur J, Prasad KK, Sinha SK, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. Dig Dis Sci 2013;58:2594-8.
75. Klaus J, Spaniol U, Adler G, Mason RA, Reinshagen M, von Tirpitz CC. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease. BMC Gastroenterol 2009;9:61.
76. Scribano ML. Role of Rifaximin in Inflammatory Bowel Disease Treatment. Mini Rev Med Chem [Epub ahead of print on July 21, 2015].
77. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012;142:473-481.
78. Jigaranu AO, Nedelciuc O, Blaj A, Badea M, Mihai C, Diculescu M, et al. Is rifaximin effective in maintaining remission in Crohn's disease? Dig Dis 2014;32:378-83.
79. Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis 2006;12:335.
80. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroidtreatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999;44:1220-1.
81. Andrews P, Borody TJ, Shortis NP, Thompson S. Bacteriotherapy for chronic constipation - long term follow up. Gastroenterology 1995;108:A563.
82. Pinn D, Aroniadis O, Brandt LJ. Follow up study of fecal microbiota transplantation (FMT) for the treatment of refractory irritable bowel syndrome (IBS). Am J Gastroenterol 2013;108:S1862.
83. Borody TJ, George L, Andrews P, Brandi S, Noonan S, Cole P, et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989;150:604.
84. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2014;8:1569-81.
85. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015;149:102-9.
86. Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, et al. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology 2015;149:223-37.
87. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health 2006;2:24.
88. Iskandar HN, Cassell B, Kanuri N, Gyawali CP, Gutierrez A, Dassopoulos T, et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol 2014;48:423-9.
89. Peters SL, Muir JG, Gibson PR. Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:1104-15.
90. Miller V, Carruthers HR, Morris J, Hasan SS, Archbold S, Whorwell PJ. Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. Aliment Pharmacol Ther 2015;41:844-55.
91. Moser G, Tragner S, Gajowniczek EE, Mikulits A, Michalski M, Kazemi-Shirazi L, et al. Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2013;108:602-9.
92. Lea R, Houghton LA, Calvert EL, Larder S, Gonsalkorale WM, Whelan V, et al. Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:635-42.
93. Whorwell PJ, Houghton LA, Taylor EE, Maxton DG. Physiological effects of emotion: assessment via hypnosis. Lancet 1992;340:69-72.
94. Lowen MB, Mayer EA, Sjoberg M, Tillisch K, Naliboff B, Labus J, et al. Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome. Aliment Pharmacol Ther 2013;37:1184-97.
95. Keefer L, Taft TH, Kiebles JL, Martinovich Z, Barrett TA, Palsson OS. Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. Aliment Pharmacol Ther 2013;38:761-71.
96. Mawdsley JE, Jenkins DG, Macey MG, Langmead L, Rampton DS. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Am J Gastroenterol 2008;103:1460-9.
97. Emami MH, Gholamrezaei A, Daneshgar H. Hypnotherapy as an adjuvant for the management of inflammatory bowel disease: a case report. Am J Clin Hypn 2009;51:255-62.
98. Knowles SR, Monshat K, Castle DJ. The efficacy and methodological challenges of psychotherapy for adults with inflammatory bowel disease: a review. Inflamm Bowel Dis 2013;19:2704-15.
99. Timmer A, Preiss JC, Motschall E, Rucker G, Jantschek G, Moser G. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2011: CD006913.
100. Perera LP, Ananthakrishnan AN, Guilday C, Remshak K, Zadvornova Y, Naik AS, et al. Dyssynergic defecation: a treatable cause of persistent symptoms when inflammatory bowel disease is in remission. Dig Dis Sci 2013;58:3600-5.